## Congress of the United States

## House of Representatives

COMMITTEE ON OVERSIGHT AND REFORM 2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225–5051 MINORITY (202) 225–5074 http://oversight.house.gov

May 13, 2019

Dr. Robert Grant Professor of Medicine University of California, San Francisco 1700 Owens Street, Suite 316 San Francisco, CA 94158

Dear Dr. Grant:

The Committee on Oversight and Reform invites you to testify at a hearing on Thursday, May 16, 2019, at 10:00 a.m., in Room 2154 of the Rayburn House Office Building.

The topic of the hearing is "HIV Prevention Drug: Billions in Corporate Profits After Millions in Taxpayer Investments." The hearing will examine Gilead's pricing of Truvada and the federally-funded research that led to the approval of Truvada for pre-exposure prophylaxis, or PrEP.

The enclosed Witness Instruction Sheet provides additional information for witnesses appearing before the Committee. Please note the procedures for submitting testimony at least two days before the hearing. If you have any questions, please contact Committee staff at (202) 225-5051.

Sincerely,

Elijah E. Cummings

Chairman

Enclosure

cc: The Honorable Jim Jordan, Ranking Member

## **Witness Instruction Sheet**

- 1. Witnesses should provide their testimony via e-mail to Oversight\_Clerks@mail.house.gov no later than 10:00 a.m. two business days prior to he hearing.
- 2. Witnesses should also provide a short biographical summary and include it with the electronic copy of testimony provided to the Clerk.
- 3. At the hearing, each witness will be asked to summarize his or her written testimony in five minutes or less in order to maximize the time available for discussion and questions. Written testimony will be entered into the hearing record and may extend to any reasonable length.
- 4. Written testimony will be made publicly available and will be posted on the Committee's website.
- 5. The Committee does not provide financial reimbursement for witness travel or accommodations. Witnesses with extenuating circumstances, however, may submit a written request for such reimbursements to Robin Butler, Financial Administrator, 2157 Rayburn House Office Building, at least one week prior to the hearing. Reimbursements will not be made without prior approval.
- 6. Witnesses with disabilities should contact Committee staff to arrange any necessary accommodations.
- 7. Please note that Committee Rule 16(b) requires counsel representing an individual or entity before the Committee or any of its subcommittees, whether in connection with a request, subpoena, or testimony, promptly submit the attached notice of appearance to the Committee.

For inquiries regarding these rules and procedures, please contact the Committee on Oversight and Reform at (202) 225-5051.

## **Truth in Testimony Disclosure Form**

In accordance with Rule XI, clause 2(g)(5)\*, of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Oversight and Reform
Subcommittee:
Hearing Date: May 16, 2019
Hearing Title :
HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments.
Witness Name: Robert M Grant, MD
Position/Title: Professor of Medicine
Witness Type: © Governmental © Non-governmental
Are you representing yourself or an organization? © Self © Organization
If you are representing an organization, please list what entity or entities you are representing:
If you are a <u>non-governmental witness</u> , please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current calendar year and previous two calendar years. Include the source and amount of each grant or contract. If necessary, attach additional sheet(s) to provide more information.
NIH 5R01AI118575-03 (Grant, PI) 05/01/15 – 04/30/20 6.00 Calendar \$344,040 (direct costs)
If you are a <u>non-governmental witness</u> , please list any contracts or payments originating with a foreign government and related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current year and previous two calendar years. Include the amount and country of <u>origin of each contract or payment.</u> If necessary, attach additional sheet(s) to provide more information.
None

Knowingly providing material false information to this committee/subcommaterial information from this committee/subcommittee, is a crime (18 U made part of the hearing record.	, , , ,
Barout	5/13/19
Witness signature	Date

If you are a non-governmental witness, please ensure that you attach the following documents to this disclosure. Check both boxes to acknowledge that you have done so.

☑ Written statement of proposed testimony

 ▼ Curriculum vitae **Brief Bio** 

**False Statements Certification** 

\*Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

- (5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.
- (B) In the case of a witness appearing in a nongovernmental capacity, a written statement of proposed testimony shall include a curriculum vitae and a disclosure of any Federal grants or contracts, or contracts or payments originating with a foreign government, received during the current calendar year or either of the two previous calendar years by the witness or by an entity represented by the witness and related to the subject matter of the hearing.
  - (C) The disclosure referred to in subdivision (B) shall include—
  - (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and
  - (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.
- (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form not later than one day after the witness appears.